Gall, Henning http://orcid.org/0000-0001-7016-7373
Vachiéry, Jean-Luc
Tanabe, Nobuhiro
Halank, Michael
Orozco-Levi, Mauricio
Mielniczuk, Lisa
Chang, MiKyung
Vogtländer, Kai
Grünig, Ekkehard
Funding for this research was provided by:
Bayer AG and Merck Sharp and Dohme
Article History
Received: 9 November 2017
Accepted: 16 February 2018
First Online: 22 February 2018
Change Date: 3 April 2018
Change Type: Correction
Change Details: The original version of this article unfortunately contained a mistake. In the “Results” section, the percentage of patients with inoperable or persistent/recurrent CTEPH included in the study was reported as 85%. This has been corrected to 68% with this erratum.
Compliance with Ethical Standards
:
: The CAPTURE study was supported by Bayer AG and Merck Sharp and Dohme. Editorial support was provided by Adelphi Communications Ltd, supported by Bayer AG. HG reports personal fees from Actelion, AstraZeneca, Bayer AG, GSK, Janssen Cilag, Lilly, Pfizer, and United Therapeutics. J-LV reports grants from Actelion, Bayer AG, GSK, Lilly, and Merck, and holding the Actelion Chair for research in PH within his institution. NT reports lecture honoraria from Actelion, Bayer Yakuhin, Daiichi-Sankyo, and being a member of an endowed department with Actelion. MH reports board membership for Actelion, Bayer AG, GSK, and Novartis; lecture fees from Actelion, AstraZeneca, Bayer AG, GSK, Lilly, MSD, Novartis, and Pfizer; and personal fees from Actelion, Bayer AG, GSK, Lilly, and Novartis. MO-L has nothing to disclose. LM reports personal fees from Actelion and Bayer AG, and consulting, speaker fees, and research funding from Actelion and Bayer AG. MC reports employment by Bayer AG. KV reports employment by Bayer AG. EG reports grants from Actelion, Bayer AG, GSK, Lilly, and Pfizer; personal fees from Bayer AG, Milteny, Novartis, and United Therapeutics; and non-financial support from Alexion.
: The study was carried out within an approved indication in accordance with guidelines and regulations of EMA, FDA and applicable local laws and regulations. ICH-GCP guidelines were followed wherever possible. In all countries where reference to an IEC/IRB is required, documented approval for appropriate IEC/IRB will be obtained for all participating centers prior to study start.
: Informed consent was obtained from all individual participants included in this study.